Novartis announced positive results from its Cosentyx focused PREVENT trial, advancing the drug in potential new indication for patients with axial spondyloarthritis. The phase III study met its 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA), showing a considerable and clinically meaningful reduction in disease activity. Novartis has also submitted
Recently Novartis has been keen to demonstrate its digital progress so far, and ahead of today’s full year results conference at its HQ in Basel, Switzerland, it showcased some of its advances to the media. One of its most noteworthy achievements is the new digitally-enabled nerve centre on its Basel campus which allows the company to monitor
The international pharmaceutical company has stated that it will relocate its UK headquarters to London’s White City Place Campus, an area that has emerged as a UK life sciences hotbed. The relocation will see Novartis UK and approximately 600 of its staff leave behind its longstanding base in Frimley, Surrey, to be closer to the
Novartis has recently released trial data showing that Cosentyx was shown to be significantly more effective in treating patients with psoriasis when compared to the Johnson & Johnson’s rival biologic Stelara. According to the published results from the head-to-head CLARITY study, 66.5% of patients treated with Cosentyx achieved the primary endpoint PASI 90 (a 90%
Allergan is set to expand its research and development programme on non-alcoholic steatohepatitis (NASH) through a partnership with Novartis that will test a new combination therapy approach for the condition. The pharmaceutical firms have signed a clinical trial agreement under which Novartis will carry out a Phase IIb study testing Allergan’s cenicriviroc (CVC), a once-daily,
Novartis have released data from a phase III clinical trial suggesting that their somatostatin analogue, Signifor, could be effective for the growth hormone disorder, acromegaly. The recent clinical trial assessed a once-monthly intramuscular formulation, named Signifor LAR, in patients with acromegaly where standard therapies had been ineffective. Signifor has already been approved by regulators in
US regulators have granted Novartis’ experimental muscle wasting drug, bimagrumab, ‘breakthrough’ status, potentially granting it fast-track to being approved. The US Food and Drug Administration (FDA) has decided to grant BYM338 (bimagrumab) a potential breakthrough because, if it is approved, it could become the first treatment for patients with sporadic inclusion body myositis, a rare
Novartis’ Alcon unit has released Jetrea in the UK, its first market. The launch is under a month after European Commission approved Jetrea for the treatment of vitreomacular traction. Vitreomacular traction (VMT) is an age-related progressive, sight-threatening condition. Jetrea was approved for VMT, including when associated with macular hole of diameter less than or equal
Novartis have announced that they will be expanding their presence in Ireland, setting up a business services centre in Dublin. The move, which will create 100 additional jobs, will combine the digital marketing, sales force training and medical communications services for the organisation. The centre is being established at Novartis’ existing campus in Beech Hill,
UK drugs watchdog, NICE, have endorsed the use of Lucentis on the NHS to treat visual impairment caused by diabetic macular oedema after Novartis submitted a revised patient access scheme (PAS) and new drug data. The National Institute for Health and Clinical Excellence published the final draft guidance after a rapid review of the original
